Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,755 | 174 | 92.2% |
| Education | $399.84 | 11 | 7.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $961.11 | 31 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $561.92 | 12 | $0 (2024) |
| Janssen Biotech, Inc. | $495.89 | 18 | $0 (2023) |
| Genentech USA, Inc. | $472.27 | 27 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $448.61 | 21 | $0 (2022) |
| Amgen Inc. | $362.35 | 9 | $0 (2019) |
| Celgene Corporation | $309.56 | 10 | $0 (2022) |
| GlaxoSmithKline, LLC. | $286.09 | 4 | $0 (2024) |
| PFIZER INC. | $181.12 | 7 | $0 (2024) |
| Incyte Corporation | $157.47 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $472.11 | 4 | AstraZeneca Pharmaceuticals LP ($125.00) |
| 2023 | $298.99 | 3 | Janssen Biotech, Inc. ($205.26) |
| 2022 | $396.39 | 20 | Novartis Pharmaceuticals Corporation ($81.82) |
| 2021 | $135.81 | 2 | GlaxoSmithKline, LLC. ($123.89) |
| 2020 | $254.80 | 10 | AstraZeneca Pharmaceuticals LP ($136.21) |
| 2019 | $1,118 | 48 | E.R. Squibb & Sons, L.L.C. ($316.47) |
| 2018 | $1,186 | 49 | Amgen Inc. ($220.02) |
| 2017 | $1,293 | 49 | E.R. Squibb & Sons, L.L.C. ($403.64) |
All Payment Transactions
185 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/07/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 02/08/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 02/01/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $98.49 | General |
| Category: Oncology | ||||||
| 01/24/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $123.62 | General |
| Category: Hematology | ||||||
| 09/19/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, CARVYKTI | Food and Beverage | In-kind items and services | $124.94 | General |
| Category: Oncology | ||||||
| 07/12/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $93.73 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 03/07/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $80.32 | General |
| Category: Oncology | ||||||
| 12/23/2022 | PFIZER INC. | XTANDI (Drug), ORGOVYX | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2022 | Sobi, Inc | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/28/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Education | In-kind items and services | $26.98 | General |
| Category: ONCOLOGY | ||||||
| 11/10/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.84 | General |
| Category: Hematology | ||||||
| 11/03/2022 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: BioOncology | ||||||
| 10/27/2022 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $22.10 | General |
| Category: ONCOLOGY | ||||||
| 10/20/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.79 | General |
| Category: Oncology | ||||||
| 09/30/2022 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: Oncology | ||||||
| 09/22/2022 | GlaxoSmithKline, LLC. | BLENREP (Biological) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2022 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: ONCOLOGY | ||||||
| 09/09/2022 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: ONCOLOGY | ||||||
| 09/01/2022 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $24.01 | General |
| Category: Oncology | ||||||
| 08/25/2022 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $17.66 | General |
| 08/18/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: ONCOLOGY | ||||||
| 08/10/2022 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: Oncology | ||||||
| 06/16/2022 | Astellas Pharma US Inc | PADCEV (Drug) | Food and Beverage | In-kind items and services | $12.69 | General |
| Category: Oncology | ||||||
| 06/09/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: Oncology | ||||||
| 05/26/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 764 | 1,972 | $572,508 | $133,042 |
| 2022 | 7 | 642 | 1,400 | $370,758 | $87,974 |
| 2021 | 8 | 472 | 873 | $217,922 | $58,674 |
| 2020 | 9 | 632 | 1,291 | $284,424 | $73,409 |
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 161 | 863 | $211,858 | $51,614 | 24.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 258 | 698 | $195,734 | $47,610 | 24.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 148 | 187 | $87,202 | $17,967 | 20.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 81 | 81 | $43,959 | $7,372 | 16.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 82 | 100 | $18,308 | $4,595 | 25.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 22 | 29 | $11,549 | $3,078 | 26.6% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 12 | 14 | $3,898 | $806.40 | 20.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 197 | 477 | $125,778 | $32,237 | 25.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 137 | 539 | $124,858 | $29,151 | 23.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 100 | 118 | $52,027 | $11,138 | 21.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 111 | 162 | $27,926 | $8,043 | 28.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 55 | 55 | $28,150 | $5,205 | 18.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 28 | 28 | $9,373 | $1,598 | 17.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 14 | 21 | $2,645 | $602.72 | 22.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 164 | 390 | $97,117 | $28,189 | 29.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 67 | 176 | $38,727 | $9,765 | 25.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 96 | 152 | $24,639 | $6,403 | 26.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 45 | 45 | $21,491 | $4,071 | 18.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 22 | 22 | $9,255 | $2,143 | 23.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 14 | 19 | $6,672 | $2,064 | 30.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 13 | $7,809 | $2,021 | 25.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 28 | 30 | $4,886 | $1,948 | 39.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 14 | 15 | $3,810 | $1,485 | 39.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 11 | 11 | $3,516 | $585.84 | 16.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 177 | 404 | $90,950 | $22,924 | 25.2% |
About Dr. John Ponugupati, M.D
Dr. John Ponugupati, M.D is a Internal Medicine healthcare provider based in South Charleston, West Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/07/2008. The National Provider Identifier (NPI) number assigned to this provider is 1124274303.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Ponugupati, M.D has received a total of $5,155 in payments from pharmaceutical and medical device companies, with $472.11 received in 2024. These payments were reported across 185 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($4,755).
As a Medicare-enrolled provider, Ponugupati has provided services to 2,510 Medicare beneficiaries, totaling 5,536 services with total Medicare billing of $353,099. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location South Charleston, WV
- Active Since 08/07/2008
- Last Updated 12/30/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1124274303
Products in Payments
- OPDIVO (Biological) $686.98
- DARZALEX (Biological) $422.53
- LYNPARZA (Drug) $324.17
- Revlimid (Drug) $230.68
- ZEJULA (Drug) $159.62
- IMFINZI (Drug) $157.16
- REBLOZYL (Biological) $143.46
- KEYTRUDA (Biological) $142.68
- JEMPERLI (Biological) $125.00
- Avastin (Biological) $123.03
- IMBRUVICA (Drug) $109.70
- SPRYCEL (Drug) $98.61
- TIVDAK (Biological) $98.49
- JAKAFI (Drug) $97.48
- TASIGNA (Drug) $95.76
- Kyprolis (Biological) $95.26
- RYDAPT (Drug) $94.84
- Rezlidhia (Drug) $93.73
- Perjeta (Biological) $91.62
- TECENTRIQ (Biological) $90.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in South Charleston
Dr. Christopher Skaggs, M.d, M.D
Internal Medicine — Payments: $15,988
Dr. Dina Criniti, D.o, D.O
Internal Medicine — Payments: $14,894
Dr. Franklin Moore, D.o, D.O
Internal Medicine — Payments: $8,122
Mr. Ananthan Krishnathas, Md, MD
Internal Medicine — Payments: $2,921
Dr. Elizabeth Brown, M.d, M.D
Internal Medicine — Payments: $1,758
Dr. David Mullett, M.d, M.D
Internal Medicine — Payments: $991.25